CN101642434B - Levofloxacin lactate liposome sodium chloride injection and preparation method thereof - Google Patents
Levofloxacin lactate liposome sodium chloride injection and preparation method thereof Download PDFInfo
- Publication number
- CN101642434B CN101642434B CN2009101469491A CN200910146949A CN101642434B CN 101642434 B CN101642434 B CN 101642434B CN 2009101469491 A CN2009101469491 A CN 2009101469491A CN 200910146949 A CN200910146949 A CN 200910146949A CN 101642434 B CN101642434 B CN 101642434B
- Authority
- CN
- China
- Prior art keywords
- sodium chloride
- levofloxacin lactate
- liposome
- chloride injection
- lactate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- ONDRRTIAGBDDKP-PPHPATTJSA-N 294662-18-3 Chemical compound CC(O)C(O)=O.C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 ONDRRTIAGBDDKP-PPHPATTJSA-N 0.000 title claims abstract description 88
- 239000002502 liposome Substances 0.000 title claims abstract description 68
- 239000008354 sodium chloride injection Substances 0.000 title claims abstract description 45
- 238000002360 preparation method Methods 0.000 title abstract description 26
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 48
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 48
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 24
- 239000011780 sodium chloride Substances 0.000 claims abstract description 24
- 238000001704 evaporation Methods 0.000 claims abstract description 18
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 14
- 239000000243 solution Substances 0.000 claims abstract description 14
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 11
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 24
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical group [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims description 20
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 19
- 230000008020 evaporation Effects 0.000 claims description 17
- 238000003756 stirring Methods 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- 125000002252 acyl group Chemical group 0.000 claims description 12
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 claims description 10
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 10
- 235000006708 antioxidants Nutrition 0.000 claims description 10
- 235000010265 sodium sulphite Nutrition 0.000 claims description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 9
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 9
- 239000000337 buffer salt Substances 0.000 claims description 9
- 239000003960 organic solvent Substances 0.000 claims description 9
- 239000008363 phosphate buffer Substances 0.000 claims description 9
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims description 8
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims description 8
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims description 8
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 8
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims description 8
- 239000000839 emulsion Substances 0.000 claims description 8
- 235000011187 glycerol Nutrition 0.000 claims description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 6
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 229940083466 soybean lecithin Drugs 0.000 claims description 6
- 239000008347 soybean phospholipid Substances 0.000 claims description 6
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 5
- 229930003427 Vitamin E Natural products 0.000 claims description 5
- 239000007853 buffer solution Substances 0.000 claims description 5
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 5
- 235000019165 vitamin E Nutrition 0.000 claims description 5
- 229940046009 vitamin E Drugs 0.000 claims description 5
- 239000011709 vitamin E Substances 0.000 claims description 5
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 claims description 4
- 235000010469 Glycine max Nutrition 0.000 claims description 4
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 4
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 4
- 229960000367 inositol Drugs 0.000 claims description 4
- 229940042880 natural phospholipid Drugs 0.000 claims description 4
- -1 palmityl phosphatidyl glycerols Chemical class 0.000 claims description 4
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 4
- 239000007974 sodium acetate buffer Substances 0.000 claims description 4
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 3
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims description 3
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims description 2
- DSNRWDQKZIEDDB-SQYFZQSCSA-N 1,2-dioleoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC DSNRWDQKZIEDDB-SQYFZQSCSA-N 0.000 claims description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 2
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 claims description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 2
- 102000002322 Egg Proteins Human genes 0.000 claims description 2
- 108010000912 Egg Proteins Proteins 0.000 claims description 2
- 241000287828 Gallus gallus Species 0.000 claims description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 2
- 244000068988 Glycine max Species 0.000 claims description 2
- 244000147568 Laurus nobilis Species 0.000 claims description 2
- 235000017858 Laurus nobilis Nutrition 0.000 claims description 2
- 235000005212 Terminalia tomentosa Nutrition 0.000 claims description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 2
- 239000008351 acetate buffer Substances 0.000 claims description 2
- 239000000872 buffer Substances 0.000 claims description 2
- 239000007979 citrate buffer Substances 0.000 claims description 2
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 claims description 2
- 238000005984 hydrogenation reaction Methods 0.000 claims description 2
- 239000000787 lecithin Substances 0.000 claims description 2
- 235000010445 lecithin Nutrition 0.000 claims description 2
- 229940067606 lecithin Drugs 0.000 claims description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 2
- 210000004681 ovum Anatomy 0.000 claims description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 2
- 150000008105 phosphatidylcholines Chemical class 0.000 claims description 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 2
- 239000001509 sodium citrate Substances 0.000 claims description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 150000003722 vitamin derivatives Chemical class 0.000 claims 1
- 239000007924 injection Substances 0.000 abstract description 10
- 238000002347 injection Methods 0.000 abstract description 10
- 239000002245 particle Substances 0.000 abstract description 6
- 239000000463 material Substances 0.000 abstract 2
- 229940009976 deoxycholate Drugs 0.000 abstract 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 abstract 1
- 238000004383 yellowing Methods 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 10
- 239000000203 mixture Substances 0.000 description 9
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 230000007774 longterm Effects 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 230000008859 change Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000013618 particulate matter Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000002950 deficient Effects 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 2
- 206010061623 Adverse drug reaction Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010070863 Toxicity to various agents Diseases 0.000 description 2
- 230000000680 avirulence Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 229960004217 benzyl alcohol Drugs 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229960001699 ofloxacin Drugs 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- SPOMEWBVWWDQBC-UHFFFAOYSA-K tripotassium;dihydrogen phosphate;hydrogen phosphate Chemical compound [K+].[K+].[K+].OP(O)([O-])=O.OP([O-])([O-])=O SPOMEWBVWWDQBC-UHFFFAOYSA-K 0.000 description 2
- 241000606161 Chlamydia Species 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002632 lipids Chemical group 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- QQVIHTHCMHWDBS-UHFFFAOYSA-N perisophthalic acid Natural products OC(=O)C1=CC=CC(C(O)=O)=C1 QQVIHTHCMHWDBS-UHFFFAOYSA-N 0.000 description 1
- ULSIYEODSMZIPX-UHFFFAOYSA-N phenylethanolamine Chemical compound NCC(O)C1=CC=CC=C1 ULSIYEODSMZIPX-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention provides a levofloxacin lactate liposome sodium chloride injection and a preparation method thereof. The levofloxacin lactate liposome sodium chloride injection is characterized by being prepared with the following components according to parts by weight: 1 part of levofloxacin lactate, 5-15 parts of phospholipid, 0.5-1.5 parts of cholesterol, 0.5-2 parts of deoxycholate, 2-10 parts of sodium chloride and 0.5-1.5 parts of antioxidant. The invention adopts specific auxiliary materials to proportion with the original auxiliary materials and adopts the reverse phase evaporation method to prepare the levofloxacin lactate liposome sodium chloride injection of the invention, solving problems of unqualified levofloxacin lactate injection clarity and insoluble particles, and yellowing of solution color in the prior art. The invention provides a stable levofloxacin lactate liposome sodium chloride injection featuring long-time laying aside.
Description
Technical field
The present invention relates to a kind of Liposomal formulation, be specifically related to levofloxacin lactate liposome sodium chloride injection and preparation method thereof, belong to medical technical field.
Background technology
Levofloxacin lactate, chemical name is: its chemical name is: (-)-(s)-9-fluoro-2,3-dihydro-3-methyl isophthalic acid 0-(4-methyl isophthalic acid-piperazinyl)-7-oxygen-7h-pyrido [1,2,3 ,-de]-[1,4] benzoxazinyl-6-carboxylic acid lactate semihydrate, molecular formula: C
18H
20FN
3O
4C
3H
6O
31/2H
2O, molecular weight: 460.41, structural formula is:
Levofloxacin lactate is the levo form of ofloxacin, and its antibacterial activity is about 2 times of ofloxacin, and its main mechanism suppresses bacterium DNA replication for suppressing DNA of bacteria gyrase activity.Have has a broad antifungal spectrum, characteristics that antibacterial action is strong, to most enterobacteriaceae lactobacteriaceaes, stronger antibacterial activity is arranged as kerekou pneumonia diphtheria, Proteus, salmonella typhosa, Shigella, hemophilus influenza, part escherichia coli, bacillus pyocyaneus, gonococcus etc.; Gram positive bacterias such as part staphylococcus, streptococcus pneumoniae, micrococcus scarlatinae, Hemolytic streptococcus and legionella, mycoplasma, chlamydia also there are good antibacterial action, but relatively poor to anaerobe and enterococcal effect.
At present, existing injection of levofloxacin lactate injection and injectable powder approval listing, but all exist long-term the placement to have clarity and the underproof problem of particulate matter, and the solution colour flavescence, do not meet the quality standard requirement, had a strong impact on the safety of clinical use.Chinese patent CN101292985A discloses a kind of preparation method of levofloxacin Lactate freeze-dried injection, and it does not fundamentally change the problem of above-mentioned existence.
The inventor is through research, beyond thought discovery is applied to a kind of novel form liposome of targeting drug delivery system in the levofloxacin lactate ejection preparation, not only obtained the Liposomal formulation effect, but also solved the clarity of levofloxacin lactate injection and particulate matter is defective, the problem of solution colour flavescence, obtain unexpected invention effect, thereby finished the present invention.
Liposome (liposomes) is dispersed in phospholipid by Britain scholar Bangham and Standish at first and finds when carrying out electron microscopic observation in the water.Phospholipid is dispersed in and forms multilamelar vesicles, every layer of bilayer that is lipid in the water naturally; Separated by water between vesicle central authorities and each layer, the about 4nm of bilayer thickness, the bimolecular folliculus with this similar biofilm structure became liposome afterwards.
Liposome research is that liposome is meant that the earliest the natural grease compounds is suspended in the vesicle with double seal structure that forms in the water, now also can be prepared by the phosphatide cpd of synthetic when previous very active field.People such as late 1960s Rahman at first use liposome as pharmaceutical carrier, liposome is fit to vivo degradation, avirulence and non-immunogenicity, particularly great number tested data proof liposome can improve the Drug therapy index, reduces drug toxicity and reduce drug side effect as pharmaceutical carrier, and reduces advantage such as drug dose.
Summary of the invention
Defective at prior art levofloxacin lactate injection clarity and particulate matter, and the problem of solution colour flavescence, the object of the present invention is to provide a kind of levofloxacin lactate liposome sodium chloride injection stable, that can place for a long time, specifically, by specific adjuvant and supplementary material proportioning, with making levofloxacin lactate liposome sodium chloride injection of the present invention, solved the problem of above-mentioned existence by reverse phase evaporation.
The technical scheme that the present invention solves is as follows:
The invention provides a kind of levofloxacin lactate liposome sodium chloride injection, it is characterized in that making: 1 part of levofloxacin lactate, phosphatidase 15～15 part by following parts by weight of component, 0.5～1.5 part in cholesterol, 0.5～2 part of NaTDC, 2～10 parts in sodium chloride, 0.5～1.5 part in antioxidant.
As the preferred embodiment for the present invention, above-mentioned described levofloxacin lactate liposome sodium chloride injection, it is characterized in that making: 1 part of levofloxacin lactate by following parts by weight of component, phosphatidase 16～13 part, 0.5～1 part in cholesterol, 0.85～2 part of NaTDC, 3～9 parts in sodium chloride, 0.5～1 part in antioxidant.
Above-mentioned described levofloxacin lactate liposome sodium chloride injection, if necessary, it can also comprise makes pH value be adjusted to 4.6～5.0 pharmaceutically acceptable buffer salt solution, and for example buffer salt solution is selected from one or more in phosphate buffer, citrate buffer, carbonate buffer solution, borate buffer solution, the acetate buffer.
The above-mentioned described levofloxacin lactate liposome sodium chloride injection of the present invention, phospholipid wherein, can be selected from natural phospholipid or synthetic phospholipid, natural phospholipid for example is one or more in Ovum Gallus domesticus Flavus lecithin, hydrogenation egg yolk lecithin, EPG, egg yolk lecithin acyl serine, egg yolk lecithin acyl inositol, soybean phospholipid, hydrogenated soya phosphatide, soybean phospholipid acyl glycerol, soy phosphatidylserine or the soybean phospholipid acyl inositol; Synthetic phospholipid for example is one or more in dioleoyl phospholipid phatidylcholine, distearyl acid phosphatidylcholine, dipalmitoyl phosphatidyl choline, dimyristoyl phosphatidyl choline, two Laurel phosphatidyl cholines, DOPG, distearyl acid phosphatidyl glycerol, two palmityl phosphatidyl glycerols, GLYCEROL,DIMYRISTOYL PHOSPHATIDYL or the two lauroyl phosphatidyl glycerols.
The above-mentioned described levofloxacin lactate liposome sodium chloride injection of the present invention, wherein said antioxidant, be not particularly limited, can be antioxidant pharmaceutically commonly used, for example be selected from sodium sulfite, sodium pyrosulfite, L-cysteine, thiourea, formaldehyde and close in sodium sulfite, vitamin E, ascorbyl palmitate, the butylated hydroxyarisol one or more.
The above-mentioned described levofloxacin lactate liposome sodium chloride injection of the present invention, it is by comprising the steps to make: (1) be dissolved in phospholipid, cholesterol, NaTDC and antioxidant and become oil phase in the organic solvent; (2) levofloxacin lactate is become water in or the buffer salt solution water-soluble with sodium chloride; (3) above-mentioned oil phase and water are mixed, stir and form water/oil type (w/o type) Emulsion, the heated and stirred evaporation, when reaching the thickness state, add entry or buffer salt solution again, continue the heated and stirred evaporation and remove residual organic solvent, ultrasonic, be transferred in the at a high speed even matter blender, stir even matter, promptly get the levofloxacin lactate liposome sodium chloride injection.
Wherein, above-mentioned described organic solvent for example can be selected from chloroform, ethanol, methanol, the tert-butyl alcohol, n-butyl alcohol, isopropyl alcohol, acetone, ether, benzyl alcohol, the normal hexane one or more.
As the most preferred specific embodiments of the present invention, above-mentioned described levofloxacin lactate liposome sodium chloride injection, it is characterized in that making 100 bottles of levofloxacin lactate liposome sodium chloride injection: levofloxacin lactate 10g by following component, soybean lecithin 60g, cholesterol 5g, NaTDC 15g, ascorbyl palmitate 10g, sodium chloride 90g, the potassium dihydrogen phosphate of pH value 5.0-dipotassium hydrogen phosphate buffer 10L.
As most preferred another specific embodiments of the present invention, above-mentioned described levofloxacin lactate liposome sodium chloride injection, it is characterized in that making 100 bottles of levofloxacin lactate liposome sodium chloride injection: levofloxacin lactate 20g by following component, distearyl acid phosphatidyl glycerol 200g, cholesterol 20g, NaTDC 40g, sodium sulfite 20g, sodium chloride 90g, the acetic acid of pH value 4.6-sodium-acetate buffer 2L.
As most preferred the 3rd specific embodiments of the present invention, above-mentioned described levofloxacin lactate liposome sodium chloride injection, it is characterized in that making 100 bottles of levofloxacin lactate liposome sodium chloride injection: levofloxacin lactate 30g by following component, egg yolk lecithin acyl serine 400g, cholesterol 15g, NaTDC 25g, vitamin E 15g, sodium chloride 90g, the citric acid of pH value 4.8-sodium citrate buffer 10L.
As another goal of the invention of the present invention, a kind of method for preparing above-mentioned described levofloxacin lactate liposome sodium chloride injection is provided, preparation process is:
(1) phospholipid, cholesterol, NaTDC and antioxidant are dissolved in become oil phase in the organic solvent;
(2) levofloxacin lactate is become water in or the buffer salt solution water-soluble with sodium chloride;
(3) above-mentioned oil phase and water are mixed, stir and form water/oil type (w/o type) Emulsion, the heated and stirred evaporation, when reaching the thickness state, add entry or buffer salt solution again, continue the heated and stirred evaporation and remove residual organic solvent, ultrasonic, be transferred in the at a high speed even matter blender, stir even matter, promptly get the levofloxacin lactate liposome sodium chloride injection.
Above-mentioned described preparation method, wherein said organic solvent for example can be selected from chloroform, ethanol, methanol, the tert-butyl alcohol, n-butyl alcohol, isopropyl alcohol, acetone, ether, benzyl alcohol, the normal hexane one or more.
Levofloxacin lactate liposome sodium chloride injection provided by the invention carries out stability test and investigates, and places 10 days under 60 ℃ of high temperature, illumination 4500Lx condition, and every detection index has no significant change; Accelerated test is 6 months under 40 ℃ of high temperature, relative humidity 75% ± 5% condition, and every detection index does not have significant change; Long term test is 18 months under 25 ℃ of high temperature, relative humidity 60% ± 10% condition, and every detection index does not have significant change.
Levofloxacin lactate liposome preparation provided by the invention carries out acute toxicity test, abnormal toxicity test and heat source check, and is all up to specification, and safety obtains proof.
Levofloxacin lactate liposome sodium chloride injection provided by the invention compared with prior art, has beyond thought effect, and major advantage is as follows:
(1) levofloxacin lactate is wrapped in the liposome, and it is defective to have solved long-term placement particulate matter and clarity, and the problem of solution colour flavescence has guaranteed product quality;
(2) pharmaceutical carrier liposome vivo degradation, avirulence and non-immunogenicity, and can improve the Drug therapy index, reduce drug toxicity and reduce drug side effect;
(3) adopt conventional process equipment, but commercial scale, high efficiency production, and constant product quality is a kind of uniqueness and blanket, the low-cost industrial preparation method.
The specific embodiment
Further specify the present invention by the following examples, but should not be construed as limitation of the present invention.
Embodiment 1
The preparation of levofloxacin lactate liposome sodium chloride injection
Prescription (100 bottles): levofloxacin lactate 10g
Soybean lecithin 60g
Cholesterol 5g
NaTDC 15g
Ascorbyl palmitate 10g
Sodium chloride 90g
Preparation technology
(1) 60g soybean lecithin, 5g cholesterol, 15g NaTDC and 10g ascorbyl palmitate are dissolved in the ethanol of 500ml;
(2) levofloxacin lactate 10g and sodium chloride 90g are dissolved in the potassium dihydrogen phosphate-dipotassium hydrogen phosphate buffer solution of 8000mlpH value 5.0;
(3) with the two mixing, stir, form w/o type Emulsion, the heated and stirred evaporation is when mixture reaches the thickness state, the phosphate buffer that adds 2000mlpH value 5.0 again, continue the heated and stirred evaporation and remove residual ethanol, ultrasonic 30min is transferred in the at a high speed even matter blender, stir even matter 30min, get the levofloxacin lactate liposome sodium chloride injection.
Comparative Examples 1
The preparation of levofloxacin lactate liposome
Prescription (100 bottles): levofloxacin lactate 10g
Soybean lecithin 45g
Cholesterol 4g
NaTDC 22g
Ascorbyl palmitate 18g
Sodium chloride 90g
Preparation technology
(1) 45g soybean lecithin, 4g cholesterol, 22g NaTDC and 18g ascorbyl palmitate are dissolved in the ethanol of 500ml;
(2) levofloxacin lactate 10g and sodium chloride 90g are dissolved in the potassium dihydrogen phosphate-dipotassium hydrogen phosphate buffer solution of 8000mlpH value 5.0;
(3) with the two mixing, stir, form w/o type Emulsion, the heated and stirred evaporation is when mixture reaches the thickness state, the phosphate buffer that adds 2000mlpH value 5.0 again, continue the heated and stirred evaporation and remove residual ethanol, ultrasonic 30min is transferred in the at a high speed even matter blender, stir even matter 30min, get the levofloxacin lactate liposome injection.
Embodiment 2
The preparation of levofloxacin lactate liposome sodium chloride injection
Prescription (100 bottles): levofloxacin lactate 20g
Distearyl acid phosphatidyl glycerol 200g
Cholesterol 20g
NaTDC 40g
Sodium sulfite 20g
Sodium chloride 90g
Preparation technology
(1) 200g distearyl acid phosphatidyl glycerol, 20g cholesterol, 40g NaTDC and 20g sodium sulfite are dissolved in the isopropyl alcohol of 2000ml;
(2) levofloxacin lactate 20g and sodium chloride 90g are dissolved in the 8000ml water;
(3) with the two mixing, stir, form w/o type Emulsion, the heated and stirred evaporation is when mixture reaches the thickness state, acetic acid-the sodium-acetate buffer that adds 2000mlpH value 4.6 again, continue the heated and stirred evaporation and remove residual isopropanol, ultrasonic 30min is transferred in the at a high speed even matter blender, stir even matter 30min, get the levofloxacin lactate liposome sodium chloride injection.
Comparative Examples 2
The preparation of levofloxacin lactate liposome
Prescription (100 bottles): levofloxacin lactate 20g
Distearyl acid phosphatidyl glycerol 310g
Cholesterol 32g
NaTDC 4g
Sodium sulfite 4.5g
Sodium chloride 90g
Preparation technology
(1) 310g distearyl acid phosphatidyl glycerol, 32g cholesterol, 4g NaTDC and 4.5g sodium sulfite are dissolved in the isopropyl alcohol of 2000ml;
(2) levofloxacin lactate 20g and sodium chloride 90g are dissolved in the 8000ml water;
(3) with the two mixing, stir, form w/o type Emulsion, the heated and stirred evaporation is when mixture reaches the thickness state, acetic acid-the sodium-acetate buffer that adds 2000mlpH value 4.6 again, continue the heated and stirred evaporation and remove residual isopropanol, ultrasonic 30min is transferred in the at a high speed even matter blender, stir even matter 30min, get the levofloxacin lactate liposome injection.
Embodiment 3
The preparation of levofloxacin lactate liposome sodium chloride injection
Prescription (100 bottles): levofloxacin lactate 30g
Egg yolk lecithin acyl serine 400g
Cholesterol 30g
NaTDC 25g
Vitamin E 15g
Sodium chloride 90g
Preparation technology
(1) 400g egg yolk lecithin acyl serine, 30g cholesterol, 25g NaTDC and 15g vitamin E are dissolved in the benzyl alcohol of 2000ml;
(2) levofloxacin lactate 30g and sodium chloride 90g are dissolved in the citric acid-sodium citrate buffer solution of 8000mlpH value 4.8;
(3) with the two mixing, stir, form w/o type Emulsion, the heated and stirred evaporation is when mixture reaches the thickness state, add 2000ml water again, continue the heated and stirred evaporation and remove residual benzene methanol, ultrasonic 30min is transferred in the at a high speed even matter blender, stir even matter 30min, get the levofloxacin lactate liposome sodium chloride injection.
Test example 1
The mensuration of envelop rate
Get the Liposomal formulation of embodiment preparation, the total content that high performance liquid chromatography detects levofloxacin lactate is M, selects for use column chromatography to separate liposome.
Get 1.5g sephadex G-50, soak more than the swelling 12h with the pH6.8 phosphate buffer, pack in the chromatographic column (200 * 10mm) into, with above-mentioned phosphate buffer flushing balance, get the levofloxacin lactate liposome preparation 1.1ml that embodiment 1-2 and Comparative Examples 1-2 obtain respectively, add chromatography and live the top, with phosphate buffer 50ml eluting, flow velocity 1.3ml/min, the eluent of collecting adds rupture of membranes agent (ethanol: 50ml benzyl alcohol=6: 1), mixing, high performance liquid chromatography detects the content M of levofloxacin lactate
1
Envelop rate %=M
1/ M * 100%.
Table 1 entrapment efficiency determination result
By above result as can be known, the liposome encapsulation that proportioning makes of writing out a prescription of the embodiment in the scope of the invention is very high, meets the actual production requirement substantially; And the liposome encapsulation that the outer Comparative Examples prescription proportioning of the scope of the invention makes is very low, has compared tangible gap with embodiment, is not suitable for production requirement.
Test example 2
The detection of particle diameter
Get the Liposomal formulation of embodiment 1-3 and Comparative Examples 1-2 preparation, adopt micro-image analyzer to measure the particle size distribution of liposome, result such as table 2:
Table 2 particle diameter testing result
By above result as can be known, it is spherical that the liposome that embodiment 1-3 makes shows, and particle diameter is even, and scope is 100-200nm; The liposome shape that Comparative Examples 1-2 makes is indefinite, disorderly and unsystematic, not of uniform size, and particle diameter is inhomogeneous, and scope is 300-900nm.
Study on the stability
With the sample of above each embodiment preparation and (Shangdong Changfu Jiejing Pharmaceutical Industry Co., Ltd.'s production of the levofloxacin lactate injection of listing, lot number 20081116) under 60 ℃ of high temperature, illumination 4500Lx condition, places and carried out the influence factor in 10 days and test investigation, the results are shown in Table 1; Under 40 ℃ of high temperature, relative humidity 75% ± 5% condition 6 months, carry out accelerated test and investigate, the results are shown in Table 2; Under 25 ℃ of high temperature, relative humidity 60% ± 10% condition 18 months, carry out long term test and investigate, detect the variation of every quality index, the results are shown in Table 3.
Table 1 influence factor result
Table 2 accelerated test result
Table 3 long-term test results
Quicken March, June by above found that, the levofloxacin lactate injection its colour changed into yellow of long-term December, listing 18 months the time, clarity is against regulation, and pH value descends bigger, and content reduces obviously, and related substance raises; And the sample appearance character of the present invention's preparation does not have significant change, is colourless clear liquid, and clarity, pH value, content and related substance do not have obvious variation yet.The sample stable quality after long time storage that the present invention's preparation is described is better.
The present invention is described according to preferred embodiment.Should be understood that the description of front and embodiment are just to illustrating the present invention.Under prerequisite without departing from the spirit and scope of the present invention, those skilled in the art can design multiple alternative of the present invention and improvement project, and it all should be understood to be within protection scope of the present invention.
Claims (9)
1. levofloxacin lactate liposome sodium chloride injection, it is characterized in that making: 1 part of levofloxacin lactate by following parts by weight of component, phosphatidase 15～15 part, 0.5～1.5 part in cholesterol, 0.5～2 part of NaTDC, 2～10 parts in sodium chloride, 0.5～1.5 part in antioxidant, by what comprise the steps to make: (1) is dissolved in phospholipid, cholesterol, NaTDC and antioxidant and becomes oil phase in the organic solvent; (2) levofloxacin lactate is become water in or the buffer salt solution water-soluble with sodium chloride; (3) above-mentioned oil phase and water are mixed, stir and form water/oil type Emulsion, the heated and stirred evaporation, when reaching the thickness state, add entry or buffer salt solution again, continue the heated and stirred evaporation and remove residual organic solvent, ultrasonic, be transferred in the at a high speed even matter blender, stir even matter, promptly get the levofloxacin lactate liposome sodium chloride injection.
2. levofloxacin lactate liposome sodium chloride injection according to claim 1, it is characterized in that making: 1 part of levofloxacin lactate by following parts by weight of component, phosphatidase 16～13 part, 0.5～1 part in cholesterol, 0.85～2 part of NaTDC, 3～9 parts in sodium chloride, 0.5～1 part in antioxidant.
3. levofloxacin lactate liposome sodium chloride injection according to claim 1 and 2, it is characterized in that described buffer salt solution is selected from one or more in phosphate buffer, citrate buffer, carbonate buffer solution, borate buffer solution, the acetate buffer, makes pH value be adjusted to 4.6～5.0.
4. levofloxacin lactate liposome sodium chloride injection according to claim 1 and 2, it is characterized in that described phospholipid is selected from natural phospholipid or synthetic phospholipid, wherein natural phospholipid is an Ovum Gallus domesticus Flavus lecithin, the hydrogenation egg yolk lecithin, EPG, egg yolk lecithin acyl serine, egg yolk lecithin acyl inositol, soybean phospholipid, hydrogenated soya phosphatide, soybean phospholipid acyl glycerol, in soy phosphatidylserine or the soybean phospholipid acyl inositol one or more, synthetic phospholipid is the dioleoyl phospholipid phatidylcholine, distearyl acid phosphatidylcholine, dipalmitoyl phosphatidyl choline, dimyristoyl phosphatidyl choline, two Laurel phosphatidyl cholines, DOPG, distearyl acid phosphatidyl glycerol, two palmityl phosphatidyl glycerols, in GLYCEROL,DIMYRISTOYL PHOSPHATIDYL or the two lauroyl phosphatidyl glycerols one or more.
5. levofloxacin lactate liposome sodium chloride injection according to claim 1 and 2 is characterized in that described antioxidant is selected from sodium sulfite, sodium pyrosulfite, L-cysteine, thiourea, formaldehyde and closes in sodium sulfite, vitamin E, ascorbyl palmitate, the butylated hydroxyarisol one or more.
6. levofloxacin lactate liposome sodium chloride injection according to claim 1 and 2 is characterized in that described organic solvent is selected from one or more in chloroform, ethanol, methanol, the tert-butyl alcohol, n-butyl alcohol, isopropyl alcohol, acetone, ether, benzyl alcohol, the normal hexane.
7. levofloxacin lactate liposome sodium chloride injection according to claim 1, it is characterized in that making 100 bottles of levofloxacin lactate liposome sodium chloride injection: levofloxacin lactate 10g by following component, soybean lecithin 60g, cholesterol 5g, NaTDC 15g, ascorbyl palmitate 10g, sodium chloride 90g, the potassium dihydrogen phosphate of pH value 5.0-dipotassium hydrogen phosphate buffer 10L.
8. levofloxacin lactate liposome sodium chloride injection according to claim 1, it is characterized in that making 100 bottles of levofloxacin lactate liposome sodium chloride injection: levofloxacin lactate 20g by following component, distearyl acid phosphatidyl glycerol 200g, cholesterol 20g, NaTDC 40g, sodium sulfite 20g, sodium chloride 90g, the acetic acid of pH value 4.6-sodium-acetate buffer 2L.
9. levofloxacin lactate liposome sodium chloride injection according to claim 1, it is characterized in that making 100 bottles of levofloxacin lactate liposome sodium chloride injection: levofloxacin lactate 30g by following component, egg yolk lecithin acyl serine 400g, cholesterol 15g, NaTDC 25g, vitamin e1 5g, sodium chloride 90g, the citric acid of pH value 4.8-sodium citrate buffer 10L.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009101469491A CN101642434B (en) | 2009-06-08 | 2009-06-08 | Levofloxacin lactate liposome sodium chloride injection and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009101469491A CN101642434B (en) | 2009-06-08 | 2009-06-08 | Levofloxacin lactate liposome sodium chloride injection and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101642434A CN101642434A (en) | 2010-02-10 |
| CN101642434B true CN101642434B (en) | 2011-07-20 |
Family
ID=41654594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009101469491A Expired - Fee Related CN101642434B (en) | 2009-06-08 | 2009-06-08 | Levofloxacin lactate liposome sodium chloride injection and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101642434B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102188395B (en) * | 2011-04-29 | 2012-12-05 | 石药集团中诺药业（石家庄）有限公司 | Stable meropenem injection and preparation method thereof |
| CN106606775A (en) * | 2015-10-27 | 2017-05-03 | 格里菲斯大学 | liposomal group A streptococcal vaccine |
| CN106491529A (en) * | 2016-12-08 | 2017-03-15 | 广东彼迪药业有限公司 | A kind of levofloxacin hydrochloride sodium chloride injection and preparation method thereof |
| CN115721607B (en) * | 2022-11-19 | 2023-07-21 | 华夏生生药业(北京)有限公司 | Levofloxacin lactate injection and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1850032A (en) * | 2006-02-28 | 2006-10-25 | 中国人民解放军第二军医大学 | Amphotericin B nano preparation |
| CN101095659A (en) * | 2006-06-28 | 2008-01-02 | 蔡海德 | Liposome combined medicine and method for preparing the same |
| CN101401790A (en) * | 2008-11-14 | 2009-04-08 | 山东大学 | Lavo-ofloxacin liposome and preparation method thereof |
-
2009
- 2009-06-08 CN CN2009101469491A patent/CN101642434B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1850032A (en) * | 2006-02-28 | 2006-10-25 | 中国人民解放军第二军医大学 | Amphotericin B nano preparation |
| CN101095659A (en) * | 2006-06-28 | 2008-01-02 | 蔡海德 | Liposome combined medicine and method for preparing the same |
| CN101401790A (en) * | 2008-11-14 | 2009-04-08 | 山东大学 | Lavo-ofloxacin liposome and preparation method thereof |
Non-Patent Citations (6)
| Title |
|---|
| 刘宏伟等.氧氟沙星脂质体的制备及治疗兔实验性绿脓杆菌角结膜炎的研究.《眼科研究》.1995,第13卷(第3期),第149-153页. * |
| 肖桂针等.乳酸左氧氟沙星脂质体凝胶剂的制备与质量控制.《中国医院药学杂志》.2006,第26卷(第6期),第740-742页. * |
| 肖桂针等.乳酸左氧氟沙星脂质体凝胶剂的制备与质量控制.<<中国医院药学杂志>>.2006,第26卷(第6期),第740-742页. |
| 邓意辉，李焕秋，王绍宁，张鸿.主动载药与被动载药制备盐酸左氧氟沙星脂质体.《中国抗生素杂志》.2001,第26卷(第4期),第258-260页. * |
| 陈静等.注射剂的新型赋形剂-胆盐/卵磷脂混合胶束系统.《药学进展》.2001,第25卷(第4期),第227-230页. * |
| 陈静等.注射剂的新型赋形剂-胆盐/卵磷脂混合胶束系统.<<药学进展>>.2001,第25卷(第4期),第227-230页. |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101642434A (en) | 2010-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Aboud et al. | Nanotransfersomes of carvedilol for intranasal delivery: formulation, characterization and in vivo evaluation | |
| Heiati et al. | Drug retention and stability of solid lipid nanoparticles containing azidothymidine palmitate after autoclaving, storage and lyophilization | |
| Ola et al. | Effect of formulation design and freeze-drying on properties of fluconazole multilamellar liposomes | |
| WO1995008986A1 (en) | Camptothecin formulations | |
| CN101642434B (en) | Levofloxacin lactate liposome sodium chloride injection and preparation method thereof | |
| JP2002505307A (en) | Pharmaceutical compositions and uses thereof | |
| CN101822669B (en) | Liposome injection of amoxicillin sodium sulbactam sodium medicinal composition | |
| CN101804051B (en) | Liposome injection of pharmaceutical composition of amoxicillin sodium and clavulanate potassium | |
| CN101632681B (en) | Glycerol fructose liposome drug combination injection and preparation method thereof | |
| CN101732251B (en) | Oxiracetam liposome injection | |
| CN101632634B (en) | N(2)-L-alanyl-L-glutamine liposome injection and preparation method thereof | |
| CN101766571B (en) | Cefpiramide, sodium benzoate, sodium bicarbonate pharmaceutical composite lipidosome injection | |
| CN101810610B (en) | Amoxicillin sodium flucloxacillin sodium medicine compound liposome injection | |
| CN102579351B (en) | Injection mezlocillin sodium liposome and preparation method | |
| CN101632639B (en) | Tinidazole liposome injection and preparation method thereof | |
| EP2656849A1 (en) | Liposome comprising combination of chloroquine and adriamycin and preparation method thereof | |
| CN101623264B (en) | Cefmetazole sodium proliposome preparation | |
| CA3127539A1 (en) | Lecithin vesicles | |
| CN102247324B (en) | Flumazenil liposome injection | |
| CN101804052B (en) | Liposome injection of mezlocillin sodium and sulbactam sodium pharmaceutical composition | |
| Romøren et al. | Immersion delivery of plasmid DNA: I. A study of the potentials of a liposomal delivery system in rainbow trout (Oncorhynchus mykiss) fry | |
| CN101904817B (en) | Cefsulodin sodium liposome injection | |
| JP2017071598A (en) | Method for preparing monolayer liposome composition | |
| JP2024505154A (en) | Utiderone liposome composition, manufacturing method and use thereof | |
| CN101822640B (en) | Sulbenicillin sodium liposome injection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: HAINAN YONGTIAN PHARMACEUTICAL INSTITUTE CO., LTD. Free format text: FORMER OWNER: DENG JUJUAN Effective date: 20130729 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 310016 HANGZHOU, ZHEJIANG PROVINCE TO: 570216 HAIKOU, HAINAN PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20130729 Address after: 570216 C03, Haikou Free Trade Zone, Hainan, China Patentee after: Hainan Yongtian Pharmaceutical Institute Co., Ltd. Address before: 310016 room 1, 1801 Qian Tang garden, Jianggan District Shengshi, Hangzhou, Zhejiang Patentee before: Deng Jujuan |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110720 Termination date: 20160608 |